Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of remimazolam for sedation during HIFU ablation of uterine fibroids or adenomyosis
ChiCTR2400084538Phase 4Not yet recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind, single-arm trial of remimazolam in Fibromyoma (LM) and adenomyosis, sponsored by Guangzhou Women and Children's Medical Center. Primary endpoints: Sedative effect and Bispectral index. Planned start May 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Fibromyoma (LM)adenomyosis
Beyond the preview
Go deeper on ChiCTR2400084538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084538.